Combination Therapy For Inhalation Administration
Patent No. EP4188327 (titled "Combination Therapy For Inhalation Administration") was filed by Chemo Research on Jul 30, 2021. The application was issued on May 28, 2025.
Patent Summary
A pharmaceutical composition for soft mist inhaler administration comprising a combination of an inhaled corticosteroid (ICS) with a long-acting β2-agonist (LABA) and optionally a long-acting muscarinic antagonist (LAMA) for treating respiratory diseases such as asthma and COPD. The composition is a solution of the active ingredients dissolved in an alcoholic solvent, which provides higher lung deposition compared to other pharmaceutical forms. The formulation is free of propellant, stabilizing agents, and preservatives, and is suitable for use in a soft mist inhaler.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4188327
- Application Number
- EP21755917A
- Filing Date
- Jul 30, 2021
- Status
- Granted And Under Opposition
- Apr 25, 2025
- Publication Date
- May 28, 2025
- External Links
- Slate, Register , Google Patents